Ifosfamide induced encephalopathy in a child with osteosarcoma

dc.contributor.author	Sarbay, H.
dc.contributor.author	Demir, Ü.F.
dc.contributor.author	Yılmaz, G.
dc.contributor.author	Atay, A.A.
dc.contributor.author	Malbora, B.
dc.date.accessioned	2021-12-21T08:40:30Z
dc.date.available	2021-12-21T08:40:30Z
dc.date.issued	2021
dc.identifier.issn	10781552
dc.identifier.uri	https://doi.org/10.1177/1078155220963545
dc.identifier.uri	http://dspace.yeniyuzyil.edu.tr:8080/xmlui/handle/20.500.12629/1027
dc.description.abstract	Background: Ifosfamide (IFO) is an alkylating agent used to treat broad range of malignancies. One of the life-threatening toxic effects is reversible neurotoxicity. In this report; we presented a case report of ifosfamide induced encephalopathy (IIE) in
dc.language.iso	English
dc.publisher	SAGE Publications Ltd
dc.title	Ifosfamide induced encephalopathy in a child with osteosarcoma
dc.type	Article
dc.relation.journal	Journal of Oncology Pharmacy Practice
dc.identifier.issue	5
dc.identifier.startpage	1302
dc.identifier.endpage	1306
dc.identifier.volume	27
dc.identifier.doi	10.1177/1078155220963545
dc.relation.issue	5
dc.relation.volume	27

Files in this item

Files	Size	Format	View
There are no files associated with this item.